Drugs / YD0293
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07098091 | Feb → Dec 2025 overdue | — | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YD0293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07098091 ↗ |
| Route | Oral | “YD0293 tablet for oral administration” NCT07098091 ↗ |